You just read:

Theravance Biopharma Reports Positive Top-Line Four-Week Data from Phase 2 Trial of TD-9855 for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension

News provided by

Theravance Biopharma, Inc.

Aug 01, 2018, 07:00 ET